Enzyme Or Coenzyme Containing Patents (Class 424/94.1)
  • Patent number: 10328090
    Abstract: Described herein are formulations and methods for treating, managing, or preventing sleeplessness or restlessness, for increasing focus or concentration, or for decreasing anxiety. The formulations comprise honokiol and magnolol, which are present in magnolia bark extract, in admixture with one or more polyunsaturated fatty acids, such as those found in virgin salmon oil. As compared to other lipid formulations of honokiol and magnolol, the formulations show improved stability and increased uptake.
    Type: Grant
    Filed: January 18, 2016
    Date of Patent: June 25, 2019
    Assignee: ST IP Holding AG
    Inventor: Bomi P. Framroze
  • Patent number: 10328152
    Abstract: A method of treatment is disclosed, comprising administering a composition of Cyclodextrin and reduced, nanonized L-Glutathione to a patient in need of treatment, wherein the L-Glutathione molecule is non-acetylated, non-Esterified, and non-fatty acid attached.
    Type: Grant
    Filed: August 18, 2016
    Date of Patent: June 25, 2019
    Inventors: Nayan Patel, Chinh Tran
  • Patent number: 10322170
    Abstract: The invention discloses a hemostatic composition comprising: a) a biocompatible polymer in particulate form suitable for use in hemostasis, and b) one hydrophilic polymeric component comprising reactive groups.
    Type: Grant
    Filed: March 24, 2016
    Date of Patent: June 18, 2019
    Assignees: Baxter International Inc., Baxter Healthcare SA
    Inventors: Heinz Gulle, Joris Hoefinghoff, Andreas Goessl, Katarzyna Gorna
  • Patent number: 10278909
    Abstract: The present invention relates to a composition for pharmaceutical, nutritional or cosmetic use, suitable to preserve the physiological condition and health of skin and hair and to reestablish their regenerative functions, characterized in that it comprises a mixture of carnitine, caffeine and arginine as active principle, as such or as derivatives, such as pharmacologically acceptable salts. The effect of preserving the physiologic condition and health of skin and hair, and of reestablishing their regenerative functions is mainly achieved through an increase in ATP production by skin and hair cells.
    Type: Grant
    Filed: June 25, 2015
    Date of Patent: May 7, 2019
    Assignee: Giuliani S.P.A.
    Inventors: Giammaria Giuliani, Anna Benedusi, Barbara Marzani, Antonio Mascolo, Antonio Limitone
  • Patent number: 10284587
    Abstract: The disclosed computer-implemented method for responding to electronic security incidents may include (i) identifying a plurality of security incidents that each occurred within a computing environment and call for a security response, (ii) establishing relationships among the plurality of security incidents by, for each security incident, (a) calculating a feature vector indicating at least one feature of the security incident, (b) using the feature vector to calculate a degree of similarity between the security incident and an additional security and (c) creating an association between the security incident and the additional security incident that reflects the degree of similarity between the security incident and the additional security incident, and (iii) triggering, based on the relationships among the plurality of security incidents, a security action that responds to at least the security incident and the additional security incident.
    Type: Grant
    Filed: September 14, 2016
    Date of Patent: May 7, 2019
    Assignee: Symantec Corporation
    Inventors: Brian Schlatter, Adam Glick, Akshata Krishnamoorthy Rao, Feng Li
  • Patent number: 10273296
    Abstract: Musculoskeletal fibroproliferative disorders, such as Dupuytren's disease may be treated by administering locally a TNF-? antagonist. TNF-? antagonists find particular utility in inhibiting the progression of early disease state Dupuytren's disease and other musculoskeletal fibroproliferative disorders and, in combination with extracellular matrix degradation agents (such as collagenase or matrix metalloproteinase I), treating advanced disease state Dupuytren's disease and, in particular inhibiting recurrence.
    Type: Grant
    Filed: September 11, 2015
    Date of Patent: April 30, 2019
    Assignee: OXFORD UNIVERSITY INNOVATION LIMITED
    Inventors: Jagdeep Nanchahal, Kim Suzanne Midwood
  • Patent number: 10258073
    Abstract: The present invention discloses a functional nutritional blend comprising Gynostemma pentaphyllum extract, Coleus forskohlii extract, Zingiber officinale extract and piperine, for increasing metabolic efficiency and inhibition of adipogenesis.
    Type: Grant
    Filed: May 19, 2017
    Date of Patent: April 16, 2019
    Assignee: SAMI LABS LIMITED
    Inventors: Muhammed Majeed, Kalyanam Nagabhushanam, Mitchell Chavez
  • Patent number: 10246497
    Abstract: The invention relates to PYY compounds having the amino acid in the position corresponding to position 30 of hPYY(1-36) substituted with tryptophan and derivatives thereof with a modifying group attached to the position corresponding to position 7 of hPYY(1-36). The compounds of the invention are selective Y2 receptor agonists. The invention also relates to pharmaceutical compositions comprising such PYY compounds and pharmaceutically acceptable excipients, as well as the medical use of the PYY compounds.
    Type: Grant
    Filed: November 13, 2014
    Date of Patent: April 2, 2019
    Assignee: Novo Nordisk A/S
    Inventors: Soeren Oestergaard, Kilian Waldemar Conde Frieboes, Birgit Wieczorek, Jens Kaalby Thomsen, Birgitte Schjellerup Wulff, Carsten Jessen
  • Patent number: 10245304
    Abstract: The invention provides methods of treating ?-galactosidase A deficiency. Dosage forms, methods of administration, and methods of analyzing human ?-galactosidase A are also included.
    Type: Grant
    Filed: November 14, 2016
    Date of Patent: April 2, 2019
    Assignee: SHIRE HUMAN GENETIC THERAPIES, INC.
    Inventors: Douglas A. Treco, Kenneth Loveday, Marianne Borowski
  • Patent number: 10239832
    Abstract: Described herein are compounds of Formula I, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and compounds I for use to treat or prevent diseases or conditions associated with the enzyme glucosylceramide synthase (GCS).
    Type: Grant
    Filed: October 28, 2014
    Date of Patent: March 26, 2019
    Assignee: BIOMARIN PHARMACEUTICAL INC.
    Inventor: Bing Wang
  • Patent number: 10238617
    Abstract: This disclosure provides pharmaceutical compositions comprising amino acid entities and uses thereof. Methods for improving liver function and for treating liver diseases comprising administering an effective amount of the compositions to a subject in need thereof are also disclosed.
    Type: Grant
    Filed: December 29, 2017
    Date of Patent: March 26, 2019
    Assignee: AXCELLA HEALTH INC.
    Inventors: Michael Hamill, Raffi Afeyan, Chung-Wei Lee, Harry Luithardt, David Berry
  • Patent number: 10203323
    Abstract: Disclosed herein are methods for identifying novel drug candidates.
    Type: Grant
    Filed: August 2, 2016
    Date of Patent: February 12, 2019
    Assignee: Warp Drive Bio, Inc.
    Inventors: Gregory L. Verdine, David W. White, David M. Armistead, Deborah J. Palestrant, Brian Y. Chow, Chris K. Varma, Mathew Edward Sowa
  • Patent number: 10201513
    Abstract: This disclosure provides pharmaceutical compositions comprising amino acid entities and uses thereof. Methods for improving liver function and for treating liver diseases comprising administering an effective amount of the compositions to a subject in need thereof are also disclosed.
    Type: Grant
    Filed: June 11, 2018
    Date of Patent: February 12, 2019
    Assignee: AXCELLA HEALTH INC.
    Inventors: Michael Hamill, Raffi Afeyan
  • Patent number: 10172820
    Abstract: The present invention relates to a skin preparation composition for external use having excellent antiseptic ability without using chemical antiseptics. More particularly, the present invention relates to a skin preparation composition for external use, comprising: glyceryl undecylenate having excellent antiseptic ability; and one or more mixtures of ethylhexylglycerin, glyceryl caprylate, p-anisic acid and a citrus mixed extract, thus improving antiseptic ability through the increased effects of antiseptic abilities of those materials.
    Type: Grant
    Filed: November 23, 2012
    Date of Patent: January 8, 2019
    Assignee: Amorepacific Corporation
    Inventors: Il Young Kwack, Yu Na Yun, Tae Hun Park, Jin Sol Kim, Yun Hyeok Jung, Yeon Ju Hong, Kye Ho Shin
  • Patent number: 10154983
    Abstract: Some aspects of the invention provide for a method of treating Alzheimer's Disease, Mild Cognitive Impairment, Frontotemperal Dementia, Amyotrophic Lateral Sclerosis and/or Multiple Sclerosis using polyunsaturated fatty acids which are modified in certain positions to attenuate oxidative damage by Reactive Oxygen Species (ROS) and/or suppress the rate of formation of reactive products and toxic compounds.
    Type: Grant
    Filed: April 24, 2012
    Date of Patent: December 18, 2018
    Assignee: Retrotope, Inc.
    Inventor: Mikhail S. Shchepinov
  • Patent number: 10154980
    Abstract: This invention is directed to compositions having synergistic combinations of omega-3 fatty acid such as OMEGA-3 with a tomato extract lycopene, and optionally with carnosic acid and/or lutein. More specifically, the present invention provides compositions having synergistic combinations of the aforementioned compounds, which may be used, inter alia, to inhibit/suppress inflammation via the suppression of the expression of anti-inflammatory mediators or via the suppression of the secretion of anti-inflammatory mediators from macrophages at a site of inflammation.
    Type: Grant
    Filed: December 4, 2017
    Date of Patent: December 18, 2018
    Assignee: LYCORED LTD.
    Inventors: Rachel Levy, Nurit Hadad, Tanya Sedlov, Morris Zelkha, Masha Sapojnik
  • Patent number: 10154977
    Abstract: Described herein are compositions and methods relating to particles comprising at least one component of a cellular-derived microparticle. Aspects of technology described herein relate to compositions and methods for treating inflammation, wounds, and pain.
    Type: Grant
    Filed: March 23, 2012
    Date of Patent: December 18, 2018
    Assignee: The Brigham and Women's Hospital, Inc.
    Inventors: Charles N. Serhan, Lucy V. Norling, Matthew Spite, Jesmond P. Dalli
  • Patent number: 10105312
    Abstract: A hair growth oil composition to be applied topically to the human scalp in order to encourage hair growth. The present invention accomplishes these goals through a mixture of ingredients precisely proportioned to achieve a unique chemical composition that brings about maximum results. The ingredients in the composition include coconut oil, emu oil, bhringaraj (eclipta alba), amalaki (emblica officinalis), vitamin E, and pharmaceutically acceptable excipients are described. A method of use is also disclosed.
    Type: Grant
    Filed: December 8, 2016
    Date of Patent: October 23, 2018
    Inventor: Keisha Lett
  • Patent number: 10087431
    Abstract: Provided herein are methods of using a Cas1 polypeptide to generate nucleic fragments from a DNA substrate. These methods may be performed in vitro or in vivo. Also provided are methods of screening for modulators of Cas1.
    Type: Grant
    Filed: March 2, 2011
    Date of Patent: October 2, 2018
    Assignee: The Regents of the University of California
    Inventors: Blake Wiedenheft, Kaihong Zhou, Jennifer A. Doudna
  • Patent number: 10080374
    Abstract: The present invention relates to a process for producing cheese, comprising the steps of: providing a first raw material liquid; providing a second raw material liquid; treating the first raw material liquid with a protein crosslinking enzyme to provide an enzyme-treated raw material liquid; mixing the enzyme-treated raw material liquid with the second raw material liquid to provide cheese milk; processing the cheese milk into cheese. The process produces cheese in improved yields while retaining the organoleptic properties of cheese unchanged. The invention further relates to cheese treated with a protein crosslinking enzyme, having the moisture on a fat-free basis of 67% or less and a protein profile of cheese has proteins of molecular weight of less than 66 kDa.
    Type: Grant
    Filed: June 14, 2012
    Date of Patent: September 25, 2018
    Assignee: VALIO LTD.
    Inventors: Terhi Aaltonen, Päivi Myllärinen, Ilkka Huumonen, Emmi Martikainen
  • Patent number: 10071030
    Abstract: The present invention relates to a carrier for the delivery of a nutraceutical or cosmeceutical active comprising non-neutralized tocopheryl phosphate and a hydrophobic vehicle. The present invention also relates to a formulation comprising the carrier and a nutraceutical or cosmeceutical active.
    Type: Grant
    Filed: February 4, 2011
    Date of Patent: September 11, 2018
    Assignee: Phosphagenics Limited
    Inventor: Roksan Libinaki
  • Patent number: 10058612
    Abstract: Some aspects of the invention provide for a method of treating Impaired Energy Processing Disorders and Mitochondrial Deficiencies using polyunsaturated fatty acids which are modified in certain positions to attenuate oxidative damage by Reactive Oxygen Species (ROS) and/or suppress the rate of formation of reactive products and toxic compounds.
    Type: Grant
    Filed: April 24, 2012
    Date of Patent: August 28, 2018
    Assignee: Retrotope, Inc.
    Inventor: Mikhail S. Shchepinov
  • Patent number: 10058522
    Abstract: Some aspects of the invention provide for a method of treating Wet and/or Dry Age-related Macular Degeneration, Retinitis Pigmentosa, Diabetic Retinopathy, cataracts, and/or Stargardt Disease using polyunsaturated fatty acids which are modified in certain positions to attenuate oxidative damage by Reactive Oxygen Species (ROS) and/or suppress the rate of formation of reactive products and toxic compounds.
    Type: Grant
    Filed: April 24, 2012
    Date of Patent: August 28, 2018
    Assignee: Retrotope, Inc.
    Inventor: Mikhail S. Shchepinov
  • Patent number: 10046034
    Abstract: The invention relates to a hemostatic composition in powder form comprising collagen of the fibrillar type comprising a content of fibrous collagen and/or fibrillar collagen of at least 70% by weight relative to the total weight of the collagen, and at least one monosaccharide, and optionally, at least one compound selected from coagulation factors and glycosaminoglycans. The invention further relates to a method for preparing such composition, and to a unit comprising such composition and a spraying device.
    Type: Grant
    Filed: March 21, 2017
    Date of Patent: August 14, 2018
    Assignee: BIOM'UP
    Inventors: Christian Gagnieu, Patricia Forest, Sylvain Picot
  • Patent number: 10039812
    Abstract: The invention relates to deoxyribonuclease for use in the treatment of a suspected or existing C. difficile infection; a pharmaceutical or veterinary composition or formulation comprising at least deoxyribonuclease for use in the treatment of a suspected or existing C. difficile infection; a combination therapeutic comprising at least deoxyribonuclease for use in the treatment of a suspected or existing C. difficile infection; a method of treating a mammal suspected of being infected with, or infected with, C. difficile comprising the use of at least deoxyribonuclease; a method of cleaning or sterilizing a material or product comprising the use of at least deoxyribonuclease; and a cleaning or sterilizing product impregnated with or containing at least deoxyribonuclease.
    Type: Grant
    Filed: November 4, 2015
    Date of Patent: August 7, 2018
    Assignee: London School of Hygiene and Tropical Medicine
    Inventors: Lisa Dawson, Brendan Wren
  • Patent number: 10035985
    Abstract: This invention relates to adeno-associated viral (AVV) vectors, to producer cell lines for the production of AAV vectors and to methods of producing such vectors. More specifically, the invention relates to producer cell lines adapted to increase the titer of said vectors and methods of producing AAV vectors using said producer cell lines.
    Type: Grant
    Filed: January 30, 2015
    Date of Patent: July 31, 2018
    Inventors: Yuan Zhao, Stifani Satkunanathan
  • Patent number: 10028914
    Abstract: The present invention describes a reduction type coenzyme Q10 powder, a composition thereof, and a preparation method thereof. The reduction type coenzyme Q10 powder is obtained by reacting an oxidation type coenzyme Q10 with the presence of a reducing agent, removing an organic solvent and other purities from a reaction solution after the reaction is finished to obtain an oil-soluble reduction type coenzyme Q10 liquid, and then directly performing prill formation with cold wind on an obtained reduction type coenzyme Q10 greasy substance. The obtained reduction type coenzyme Q10 powder has a lower crystallinity, and in a Cu-K[alpha] X-ray diffraction spectrum, has a strong peak at a diffraction angle 2[theta] being 18.9 DEG, and has a very strong absorption peak at a diffraction angle 2[theta] being 22.8 DEG.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: July 24, 2018
    Assignee: ZHEJIANG MEDICINE CO., LTD. XINCHANG PHARMACEUTICA FACTORY
    Inventors: Xinde Xu, Gang Chen, Xuejun Lao, Lihua Zhang, Xiaoxia Sun, Xiaoyue Jiang
  • Patent number: 10024846
    Abstract: The invention provides a method for treating or preventing diet-induced obesity in a subject comprising administering an agent in an effective amount so that expression or activity of the P2Y2 receptor is decreased or inhibited in the subject thereby treating or preventing diet-induced obesity in the subject.
    Type: Grant
    Filed: April 27, 2015
    Date of Patent: July 17, 2018
    Assignee: The United States of America as represented by the Department of Veterans Affairs
    Inventors: Bellamkonda K. Kishore, Yue Zhang, Carolyn M. Ecelbarger
  • Patent number: 9994828
    Abstract: This disclosure concerns recombinant host organisms genetically modified with a polyunsaturated fatty acid (PUFA) synthase system and one or more accessory proteins that allow for and/or improve the production of PUFAs in the host organism. The disclosure also concerns methods of making and using such organisms as well as products obtained from such organisms.
    Type: Grant
    Filed: November 26, 2014
    Date of Patent: June 12, 2018
    Assignees: Dow AgroSciences LLC, DSM IP Assets B.V.
    Inventors: Terence A. Walsh, Daniel J. Gachotte, Cory M. Larsen, Scott Bevan, P. Ann Owens-Merlo, James G. Metz, Ross Zirkle
  • Patent number: 9994831
    Abstract: The present disclosure provides compositions and methods for binding and/or cleaving a single stranded target nucleic acid. Subject compositions include a Cas9 polypeptide, a guide nucleic acid, and a PAMmer. A subject PAMmer is a single stranded oligonucleotide having a protospacer adjacent motif (PAM) sequence and at least one of: a specifity segment positioned 5? of the PAM sequence, and an orientation segment positioned 3? of the PAM sequence. In some embodiments, the Cas9 polypeptide is a variant Cas9 polypeptide having reduced nuclease activity relative to a corresponding wild type Cas9 polypeptide. In some cases, methods of binding are for visualizing single stranded target nucleic acids using a detectable label. In some cases, methods of binding are for isolating, collecting, and/or analyzing at least one of: (i) bound single stranded target nucleic acids; and (ii) polypeptides associated with bound single stranded target nucleic acids.
    Type: Grant
    Filed: December 11, 2014
    Date of Patent: June 12, 2018
    Assignee: The Regents of the University of California
    Inventors: Jennifer A. Doudna, Samuel H. Sternberg, Mitchell O'Connell, Benjamin Oakes
  • Patent number: 9956179
    Abstract: This invention discloses a process for making nanoparticles of amphiphilic copolymers by flash precipitation. Nanoparticles may be of amphiphilic copolymer alone or may contain an additive target molecule, preferably an organic active. The inclusion of additive target molecules in amphiphilic copolymer nanoparticles can alter their water solubility characteristics, fluid dynamics, and/or stability. Changing an additive target molecule's solubility and stability in a nanoparticle can make a water insoluble compound suitable for pharmaceutical administration as well as specifically target the molecule to a specific area of a patient's body. The process affords the production of nanoparticles at high absolute active content, at high yield, high productivity, and high processing rates while using unusually low amounts of amphiphilic copolymers. Furthermore, the resulting particles exhibit sufficient stability for post processing as desired.
    Type: Grant
    Filed: February 8, 2012
    Date of Patent: May 1, 2018
    Assignee: The Trustees of Princeton University
    Inventors: Brian K. Johnson, Robert K. Prud'homme
  • Patent number: 9957546
    Abstract: The present invention is directed to a phospholipid-based NIR molecular beacon, having a phospholipid moiety; with an NIR fluorophore moiety covalently linked to a phospholipid glycerol backbone and a quencher moiety covalently linked to the phospholipid glycerol backbone. Additionally, provided herein is methods of analyzing a sample for the presence of a phospholipase and methods of identifying the activity of a phospholipase in vivo utilizing phospholipid-based NIR molecular beacon.
    Type: Grant
    Filed: March 3, 2009
    Date of Patent: May 1, 2018
    Assignee: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventors: E. J. Delikatny, Anatoliy V. Popov, Gang Zheng, Theresa Mawn
  • Patent number: 9950023
    Abstract: An all-natural composition for treating acne, the composition comprising: N-acetylcysteine (NAC); Nicotinamide; Resveratrol; Rhodionin; Epigallocatechin gallate (EGCG); Vitamin A; Vitamin E; Vitamin D3, Allicin; and Propolis.
    Type: Grant
    Filed: November 21, 2014
    Date of Patent: April 24, 2018
    Inventor: Parham Michael Tabibian
  • Patent number: 9938242
    Abstract: A method for producing a compound (3), which comprises allowing a compound (1) to react with hydrogen gas in an inert solvent, in the presence of a specific chiral ligand and a ruthenium catalyst, or in the presence of an asymmetric transition metal complex catalyst previously generated from the chiral ligand and the ruthenium catalyst.
    Type: Grant
    Filed: September 17, 2015
    Date of Patent: April 10, 2018
    Assignee: Daiichi Sankyo Company, Limited
    Inventors: Tsuyoshi Ueda, Kazutoshi Ukai
  • Patent number: 9932565
    Abstract: Provided are substantially dephosphorylated forms of lysosomal storage disease (LSD) proteins, including dephosphorylated forms of iduronate-2-sulfatase (IDS, or I2D) and iduronidase (IDU), having increased ability to traverse or penetrate the blood brain barrier (BBB) relative to phosphorylated forms of the protein, and p97 conjugates thereof. Also provided are compositions comprising such dephosphorylated LSD proteins and p97 conjugates, and methods of use thereof, for instance, to treat any one or more lysosomal storage diseases, such as Hunter Syndrome (or MPS Type II).
    Type: Grant
    Filed: July 31, 2013
    Date of Patent: April 3, 2018
    Assignee: biOasis Technologies, Inc.
    Inventors: Timothy Z. Vitalis, Reinhard Gabathuler
  • Patent number: 9907809
    Abstract: The disclosure provides an oral antiviral supplement composition comprising a lysine, an ascorbic compound, a flavonoid glycoside, a threonine, and a pyridoxine. The disclosure also provides a method of reducing viral replication in a cell comprising treating a virus-infected cell with a composition of the disclosure. The disclosure further provides a method for the treatment and prophylaxis of a viral infection in a patient comprising administering a composition of the disclosure.
    Type: Grant
    Filed: April 8, 2015
    Date of Patent: March 6, 2018
    Assignee: Vymedic, LLC
    Inventors: Kenneth E. Phillips, Cynthia A. Winning
  • Patent number: 9902945
    Abstract: The present invention relates to a conjugate of cell penetrating peptide and an active ingredient; and its use. Specifically, a conjugate including a cell penetrating peptide which is a peptide comprising any one amino acid sequence of SEQ ID NO: 1 to SEQ ID NO: 156, a fragment of any one sequence of SEQ ID NO: 1 to SEQ ID NO: 156, or a peptide having above 80% homology with the above-mentioned sequence; and a composition comprising the same are disclosed.
    Type: Grant
    Filed: September 17, 2013
    Date of Patent: February 27, 2018
    Assignee: GEMVAX & KAEL CO., LTD.
    Inventor: Sang Jae Kim
  • Patent number: 9901625
    Abstract: Methods for controlling and regulating engulfment, uptake and/or transcellular transport at a stage following initial engagement of an agent to the endothelium are provided, based on the identification of CAM-mediated endocytosis and the sphingomyelin/ceramide pathway as active steps in transcellular TEM. Administration of regulators relating to the identified pathways, such as NHE1, sphingomyelinases, acid sphingomyelinase and ceramide, permit control and regulation of uptake and transcellular transport. Control and regulation of uptake and/or transcellular transport is applicable in strategies to modulate inflammation, provide controlled and/or targeted delivery of agents, control pathogenic invasion, recover action of an inhibited CAM-mediated uptake or transendothelial pathway, or provide uptake or transendothelial transport by targeting cell surface markers other than ICAM-1.
    Type: Grant
    Filed: October 15, 2012
    Date of Patent: February 27, 2018
    Assignee: UNIVERSITY OF MARYLAND, COLLEGE PARK
    Inventors: Silvia Muro-Galindo, Daniel Serrano
  • Patent number: 9896731
    Abstract: Methods and formulations for treating onocological disorders in humans using Coenzyme Q10 are described.
    Type: Grant
    Filed: February 3, 2014
    Date of Patent: February 20, 2018
    Assignee: Berg LLC
    Inventors: Niven Rajin Narain, John Patrick McCook
  • Patent number: 9856314
    Abstract: The invention relates generally to activatable antibodies and methods of making and using these activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.
    Type: Grant
    Filed: June 21, 2013
    Date of Patent: January 2, 2018
    Assignee: CYTOMX THERAPEUTICS, INC.
    Inventors: Henry Bernard Lowman, Shouchun Liu
  • Patent number: 9850525
    Abstract: The present invention relates to an isothermal method for detecting in a sample a target nucleic acid strand.
    Type: Grant
    Filed: January 28, 2015
    Date of Patent: December 26, 2017
    Assignee: Agilent Technologies, Inc.
    Inventor: Carsten-Peter Carstens
  • Patent number: 9840702
    Abstract: This invention pertains to modified compositions for use in CRISPR systems, and their methods of use. In particular, length-modified and chemically-modified forms of crRNA and tracrRNA are described for use as a reconstituted guide RNA for interaction with Cas9 of CRIPSR systems. The resultant length-modified and chemically-modified forms of crRNA and tracrRNA are economical to produce and can be tailored to have unique properties relevant to their biochemical and biological activity in the context of the CRIPSR Cas9 endonuclease system.
    Type: Grant
    Filed: December 18, 2015
    Date of Patent: December 12, 2017
    Assignee: INTEGRATED DNA TECHNOLOGIES, INC.
    Inventors: Michael Allen Collingwood, Ashley Mae Jacobi, Garrett Richard Rettig, Mollie Sue Schubert, Mark Aaron Behlke
  • Patent number: 9816080
    Abstract: Methods, systems, compositions and strategies for the delivery of WW domain-containing fusion proteins into cells in vivo, ex vivo, or in vitro via ARMMs are provided. Methods, systems, compositions and strategies for the delivery of Cas9 proteins and/or Cas9 variants into cells in vivo, ex vivo, or in vitro via fusion to ARMM associated proteins (e.g., ARRDC1 or TSG101) are also provided.
    Type: Grant
    Filed: October 30, 2015
    Date of Patent: November 14, 2017
    Assignees: President and Fellows of Harvard College, The Board of Trustees of the Leland Stanford Junior University
    Inventors: Quan Lu, Qiyu Wang, Stanley N. Cohen
  • Patent number: 9809808
    Abstract: The present invention relates to endolysin variants comprising an endolysin to which a peptide stretch with membrane or LPS disrupting activity is fused. Moreover, the present invention relates to nucleic acid molecules encoding said modified endolysin variant, vectors comprising said nucleic acid molecules and host cells comprising either said nucleic acid molecules or said vectors. In addition, the present invention relates to a method for producing said endolysin variant. Further, the present invention relates to said modified endolysin variant for use as a medicament, in particular for the treatment or prevention of Gram-negative bacterial infections, as diagnostic means, disinfectant or as cosmetic substance. The present invention also relates to the removal or reduction or prevention of Gram-negative bacterial contamination of foodstuff, of food processing equipment, of food processing plants, of surfaces coming into contact with foodstuff, of medical devices, of surfaces in hospitals and surgeries.
    Type: Grant
    Filed: August 25, 2009
    Date of Patent: November 7, 2017
    Assignee: KATHOLIEKE UNIVERSITEIT LEUVEN K.U. LEUVEN R&D
    Inventors: Yves Briers, Rob Lavigne, Guido Volckaert
  • Patent number: 9782511
    Abstract: The present invention is directed to novel non-woven fabrics containing growth and differentiation factor proteins. Said fabrics are specifically designed to accelerate tissue regeneration and wound healing processes of mammalian tissues. Furthermore, the invention provides wound dressings, pads or implants comprising the novel non-woven fabrics.
    Type: Grant
    Filed: January 15, 2016
    Date of Patent: October 10, 2017
    Assignees: Biopharm Gesellschaft Zur Biotechnologischen Entwicklung von Pharmaka MBH, Carl Freudenberg KG
    Inventors: Frank Plöger, Denis Reibel, Dirk Grafahrend, Daniel Neumüller
  • Patent number: 9757328
    Abstract: The present invention relates to formulations of gelled lysozyme achieved by the addition of water to a lysozyme suspension in a solvent, such as an alcohol, with retention of enzymatic activity. It was surprisingly discovered that lysozyme itself is a gelling substance (self-gel) and, therefore, it can be advantageously formulated into topical compositions without the addition of other gelling substances such as cellulose, starch or other polysaccharides. The activity of the lysozyme is enhanced as compared to other formulations of comprising lysozyme. The formulations contained in the present invention are useful in methods in the fields of therapeutics, disinfectants, sanitizers, personal hygiene, and cosmetics for human and veterinary use.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: September 12, 2017
    Assignee: Murami Pharma, Inc.
    Inventors: Stefano Ferrari, Roelof Rongen
  • Patent number: 9757332
    Abstract: This invention relates to a gel-like composition in which ubiquinol is dispersed and stabilized in a gel and which contains 0.2 to 5% by weight of ubiquinol, 5 to 15% by weight of gelatin, 55 to 80% by weight of carbohydrate and/or water-soluble dietary fiber, and 9 to 18% by weight of water, and further contains ascorbic acid and/or gallate type catechin.
    Type: Grant
    Filed: April 30, 2014
    Date of Patent: September 12, 2017
    Assignee: UHA MIKAKUTO CO., LTD.
    Inventors: Shinsuke Kitanaka, Yoshimi Haza, Satoshi Doi, Yasuhiro Shinka, Nobuya Sato, Akinobu Kishi, Taiji Matsukawa, Takeki Matsui, Yasumasa Yamada, Ichiro Yamada
  • Patent number: 9738067
    Abstract: A liquid injection device includes a liquid injection head and a controller that generates a driving signal including first through fourth driving pulses in one liquid drop injection period and supplies the driving signal to the liquid injection head. The discharge time period of each of the first and second driving pulses is preferably set to about (½)×Tc. The start timing of the second driving pulse is preferably set to about m×Tc (m?1) after the start of the first driving pulse. The second ink drop is preferably set to be injected at a speed of the first ink drop or higher. The start timing of the third driving pulse is preferably set to about (n+(½))×Tc (n?1) after the start of the second driving pulse. The start timing of the fourth driving pulse is preferably set to about p×Tc (p?2) after the start of the third driving pulse. The fourth ink drop is injected at a speed of the third ink drop or higher.
    Type: Grant
    Filed: December 9, 2016
    Date of Patent: August 22, 2017
    Assignee: ROLAND DG CORPORATION
    Inventors: Keisuke Misawa, Takashi Makinose, Kenji Kawagoe
  • Patent number: 9676805
    Abstract: The invention relates to a process for the purification of a contaminated organophosphorus product which comprises at least one organophosphorus compound and, as contaminant, at least one chlorine compound. It is based on the object of indicating a purification method in which the chlorine content of an organophosphorus product which comprises at least one organophosphorus compound and at least one chlorine compound as contaminant, can be reduced from originally 1000 to 100 000 ppm to a total chlorine content between 10 ppm and 10 000 ppm. This is achieved by a process with the steps: a) provision of the contaminated organophosphorus product; b) complete dissolution of the contaminated organophosphorus product in a solvent to give a contaminated solution; c) separation of the contaminated solution by means of a filter and/or by means of a membrane separation unit to give a purified solution; d) removal of the solvent from the purified solution to give a purified organophosphorus product.
    Type: Grant
    Filed: January 16, 2015
    Date of Patent: June 13, 2017
    Assignee: Evonik Degussa GmbH
    Inventors: Katrin Marie Dyballa, Robert Franke, Dirk Fridag, Markus Priske
  • Patent number: 9675554
    Abstract: Compositions of reagents are formed by forming empty liposomes, mixing the thus-formed liposomes with a sugar solution and a regent, then drying the mixture. The compositions will generally contain less than 10% w/v sucrose. Using this procedure small liposomes are formed with high entrapment efficiency. The process is useful in the production of pharmaceuticals.
    Type: Grant
    Filed: June 16, 1999
    Date of Patent: June 13, 2017
    Assignee: The Secretary of State for Defence in Her Britannic Majesty's Government of the United Kingdom of Great Britain and Northern Ireland
    Inventors: Gregory Gregoriadis, Brahim Zadi, Pramukh N Jayasekera